Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DOPAMINE D2 RECEPTOR IMAGING IN PITUITARY-ADENOMAS USING IODINE-123-EPIDEPRIDE AND SPECT
Autore:
PIRKER W; RIEDL M; LUGER A; CZECH T; ROSSLER K; ASENBAUM S; ANGELBERGER P; KORNHUBER J; DEECKE L; PODREKA I; BRUCKE T;
Indirizzi:
UNIV VIENNA,NEUROL KLIN,WAHRINGER GURTEL 18-20 A-1090 VIENNA AUSTRIA UNIV VIENNA,CLIN NUCL MED A-1090 VIENNA AUSTRIA UNIV VIENNA,CLIN INTERNAL MED 3 A-1090 VIENNA AUSTRIA UNIV VIENNA,CLIN NEUROSURG A-1090 VIENNA AUSTRIA UNIV WURZBURG,DEPT PSYCHIAT D-8700 WURZBURG GERMANY FORSCHUNGSZENTRUM SEIBERSDORF SEIBERSDORF AUSTRIA
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 12, volume: 37, anno: 1996,
pagine: 1931 - 1937
SICI:
0161-5505(1996)37:12<1931:DDRIIP>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
I-125 EPIDEPRIDE; HUMAN BRAIN; GROWTH-HORMONE; RAT-BRAIN; BROMOCRIPTINE; VISUALIZATION; PROLACTINOMAS; RADIOLIGANDS; BINDING; AGONISTS;
Keywords:
DOPAMINE; D2 RECEPTORS; EPIDEPRIDE; SPECT; PITUITARY ADENOMAS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
W. Pirker et al., "DOPAMINE D2 RECEPTOR IMAGING IN PITUITARY-ADENOMAS USING IODINE-123-EPIDEPRIDE AND SPECT", The Journal of nuclear medicine, 37(12), 1996, pp. 1931-1937

Abstract

Epidepride is a novel benzamide derivative with high affinity for D2 receptors. Epidepride, in its'231-labeled form, can be used for SPECT imaging of striatal and extrastriatal dopamine D2 receptors. The present study evaluated the usefulness of epidepride and SPECT for in vivo imaging of dopamine receptors in pituitary adenomas. Methods: SPECT imaging was performed in 19 patients with pituitary adenomas (among them9 patients had prolactinoma, 4 acromegaly, 4 clinically nonfunctioning pituitary adenoma, 1 Gushing's disease and 1 Nelson's syndrome) and 7 control subjects 180 min after intravenous bolus injection of 3.9 +/- 1.1 mCi [I-123]epidepride. The ratio target/cerebellum minus 1, reflecting specific/ nonspecific binding was used as semiquantitative measure of D2 receptor binding. Results: Eight of nine prolactinoma patients demonstrated specific binding within the adenoma. The adenoma/ cerebellum ratio 3 hr p.i. showed a wide variation with values from 2.5-33. In three prolactinomas, binding was higher than in the striatum. Specific binding within the lower range of prolactinomas (adenoma/cerebellum ratios 2 and 4.8) could be demonstrated in two of four GH-secreting adenomas. All four nonfunctioning tumors showed specific binding. The adenoma/cerebellum ratio was within the lower range of prolactinomas(5.2-7.5) in three of these patients but extremely high in one (52.3), No specific tracer uptake could be demonstrated in patients with Gushing's disease or Nelson's syndrome. The striatum/cerebellum ratio 3 hr p.i. in pituitary adenoma patients was not significantly different from control subjects (17.3 +/- 5.5 versus 17.8 +/- 6.6; patients versus control subjects). Conclusion: Epidepride appears to be an excellentligand for in vivo imaging of dopamine D2 receptors in pituitary adenomas. Epidepride SPECT could serve as a predictor for response to dopamine agonist treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/11/19 alle ore 02:32:10